Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Looby

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|May 16, 2018
Benchmarking QSP Models Against Simple Models: A Path to Improved Comprehension and Predictive PerformanceAndrew M Stein, Michael Looby
British Journal of Clinical Pharmacology|March 20, 2013
Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approachChristian Bartels, Michael Looby, Romain Sechaud, et al.
International Journal of Clinical Pharmacology and Therapeutics|September 18, 2012
Comment on the report "limitations of model-based dose selection for indacaterol in patients with chronic obstructive pulmonary disease"Michael Looby, Didier Renard, Andrew Wright, et al.
Journal of Clinical Pharmacology|November 24, 2011
Population pharmacokinetics of fingolimod phosphate in healthy participantsKai Wu, Francois Mercier, Olivier J David, et al.
British Journal of Clinical Pharmacology|October 22, 2009
Population pharmacokinetics and optimal design of paediatric studies for famciclovirKayode Ogungbenro, Ivan Matthews, Michael Looby, et al.
Respiratory Research|April 27, 2011
Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approachesDidier Renard, Michael Looby, Benjamin Kramer, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 25, 2010
Population pharmacodynamic model of the longitudinal FEV1 response to an inhaled long-acting anti-muscarinic in COPD patientsKai Wu, Michael Looby, Goonaseelan Pillai, et al.
BMC Pulmonary Medicine|December 11, 2012
A novel model-based approach for dose determination of glycopyrronium bromide in COPDHelen Arievich, Tim Overend, Didier Renard, et al.
Clinical Pharmacokinetics|May 14, 2004
Pharmacokinetics of lumiracoxib in plasma and synovial fluidGraham Scott, Christiane Rordorf, Christine Reynolds, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 25, 2021
A framework to guide dose & regimen strategy for clinical drug developmentOliver Sander, Baldur Magnusson, Inga Ludwig, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
CPT: Pharmacometrics & Systems Pharmacology|May 16, 2018
Benchmarking QSP Models Against Simple Models: A Path to Improved Comprehension and Predictive PerformanceAndrew M Stein, Michael Looby
British Journal of Clinical Pharmacology|March 20, 2013
Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approachChristian Bartels, Michael Looby, Romain Sechaud, et al.
International Journal of Clinical Pharmacology and Therapeutics|September 18, 2012
Comment on the report "limitations of model-based dose selection for indacaterol in patients with chronic obstructive pulmonary disease"Michael Looby, Didier Renard, Andrew Wright, et al.
Journal of Clinical Pharmacology|November 24, 2011
Population pharmacokinetics of fingolimod phosphate in healthy participantsKai Wu, Francois Mercier, Olivier J David, et al.
British Journal of Clinical Pharmacology|October 22, 2009
Population pharmacokinetics and optimal design of paediatric studies for famciclovirKayode Ogungbenro, Ivan Matthews, Michael Looby, et al.
Respiratory Research|April 27, 2011
Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approachesDidier Renard, Michael Looby, Benjamin Kramer, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 25, 2010
Population pharmacodynamic model of the longitudinal FEV1 response to an inhaled long-acting anti-muscarinic in COPD patientsKai Wu, Michael Looby, Goonaseelan Pillai, et al.
BMC Pulmonary Medicine|December 11, 2012
A novel model-based approach for dose determination of glycopyrronium bromide in COPDHelen Arievich, Tim Overend, Didier Renard, et al.
Clinical Pharmacokinetics|May 14, 2004
Pharmacokinetics of lumiracoxib in plasma and synovial fluidGraham Scott, Christiane Rordorf, Christine Reynolds, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 25, 2021
A framework to guide dose & regimen strategy for clinical drug developmentOliver Sander, Baldur Magnusson, Inga Ludwig, et al.
Pageof 2